Media & Investors

Corporate Profile

Calithera Biosciences is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule oncology drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment.

Stock Quote


Copyright Nasdaq. Minimum 15 minutes delayed.

In the Media

Jun 18, 2019
Calithera’s positive ENTRATA Phase 2 study demonstrating the benefit of telaglenastat in combination with everolimus in treating RCC is discussed in this June 2019 OncLive article
Jun 17, 2019
Industry news source SCRIP discusses data from the ENTRATA trial and its proof-of-concept implications for Calithera’s lead compound, telaglenastat.

Upcoming Events

More events are coming soon.